Serum contains ZMapp -- company description of monoclonal antibodies (optimized cocktail) to Ebola Virus

Company information from Mapp Biopharmaceutical (posted PDF): ZMappTM  is  the  result  of  a  collaboration  between  Mapp  Biopharmaceutical,  Inc.  and   LeafBio  (San  Diego,  CA),  Defyrus  Inc.  (Toronto,  Canada),  the  U.S.  government  and   the  Public  Health  Agency  of  Canada  (PHAC).       ZMappTM  is  composed  of  three  “humanized”  monoclonal  antibodies  manufactured  in   plants,  specifically   Nicotiana.   It  is  an  optimized  cocktail  combining  the  best   components  of  MB-­‐003  (Mapp)  and  ZMAb  (Defyrus/PHAC).     ZMappTM  was  first  identified  as  a  drug  candidate  in  January  2014  and  has  not  yet   been  evaluated  for  safety  in  humans.  As  such,  very  little  of  the  drug  is  currently   available.       Any  decision  to  use  an  experimental  drug  in  a  patient  would  be  a  decision  made  by   the  treating  physician  under  the  regulatory  guidelines  of  the  FDA.     Mapp  and  its  partners  are  cooperating  with  appropriate  government  agencies  to   increase  production  as  quickly  as  possible